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Background: Thyroid cancer is among the fastest growing malignancies; almost fifty-percent of these rapidly
increasing incidence tumors are less than or equal to 1cm in size, termed papillary thyroid microcarcinoma (PTMC).
The management of PTMC remains a controversy due to differing natural history of these patients. Epithelial cell
adhesion molecule (EpCAM) is comprised of an extracellular domain (EpEx), a single transmembrane domain and
an intracellular domain (Ep-ICD). Our group reported nuclear Ep-ICD correlated with poor prognosis in thyroid
cancer (Ralhan et al., BMC Cancer 2010,10:331). Here in, we hypothesized nuclear and cytoplasmic accumulation of
Ep-ICD and loss of membranous EpEx may aid in distinguishing metastatic from non-metastatic PTMC, which is an
important current clinical challenge. To test our hypothesis, Ep-ICD and EpEx expression levels were analyzed in
PTMC and the staining was correlated with metastatic potential of these carcinomas.
Methods: Thirty-six PTMC patients (tumor size 0.5 - 1cm; metastatic 8 cases and non-metastatic 28 cases) who
underwent total thyroidectomy were selected. The metastatic group consisted of patients who developed lymph
node or distant metastasis at diagnosis or during follow up. The patients’ tissues were stained for Ep-ICD and EpEx
using domain specific antibodies by immunohistochemistry and evaluated.
Results: PTMC patients with metastasis had higher scores for nuclear and cytoplasmic Ep-ICD immunostaining
than the patients without metastasis (1.96 ± 0.86 vs. 1.22 ± 0.45; p = 0.007 and 5.37 ± 0.33 vs. 4.72 ± 1.07;
p = 0.016, respectively). Concomitantly, the former had lower scores for membrane EpEx than the non-metastatic
group (4.64 ± 1.08 vs. 5.64 ± 1.51; p = 0.026). An index of aggressiveness, Ep-ICD subcellular localization index
(ESLI), was defined as sum of the IHC scores for accumulation of nuclear and cytoplasmic Ep-ICD and loss of
membranous EpEx; ESLI = [Ep − ICDnuc + Ep − ICDcyt + loss of membranous EpEx]. Notably, ESLI correlated
significantly with lymph node metastasis in PTMC (p = 0.008).
Conclusion: Nuclear and cytoplasmic Ep-ICD expression and loss of membranous EpEx were found to correlate
positively with metastasis in PTMC patients. In addition, ESLI had the potential to identify metastatic behavior in
PTMC which could serve as a valuable tool for solving a current dilemma in clinical practice.
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Thyroid cancer represents about 1% of all new malig-
nant diseases and is the most common endocrine malig-
nancy [1]. Ninety-four percent of thyroid cancers are
differentiated carcinomas, mainly papillary thyroid can-
cer (PTC) [1,2]. In the United States, the incidence of
thyroid cancer was approximately 37 200 new cases per
year in 2009 [3] and the estimated number of cases for
the year 2012 is 56 460 (National Cancer Institute 2012).
According to SEER 2012, thyroid cancer is among the
fastest growing malignancies with an increasing signifi-
cant trend of 6.6 (where significance indicates that there
is 95% confidence that the increase is real over the
period of time measured and not due to chance alone)
(http://seer.cancer.gov). The sharp elevation within the
past decade can be attributed, in part, to the more fre-
quent use of high-resolution ultrasound guided FNA
with the advantage of better accuracy and accessibility.
Forty-nine percent of growing incidence of thyroid can-
cer has been credited to tumors with a size of 1cm or
smaller [4]. According to the World Health Organization
classification, papillary thyroid microcarcinoma (PTMC)
is defined as papillary thyroid cancer of size less than or
equal to 1 cm in maximal diameter [5]. The prevalence
of PTMC ranges from 3.5-35.6%, and its incidence has
demonstrated an upward trend in all age groups [3,6,7].
PTMCs can be classified into two broad clinical ca-
tegories. The majority of PTMCs fall in the non-
aggressive group which do not cause any symptoms
throughout a patient’s life and are essentially very low
risk thyroid carcinomas. However, there have been
reports of patients presenting with cervical lymph node
metastasis of thyroid origin without a palpable thyroid
nodule [8] or presenting with concomitant cervical
lymph node and distant metastasis [9,10]. The survival
rate of PTMC is excellent; cancer related deaths are only
0.34% [11]. However, 2.4% – 20% of PTMCs have loco-
regional recurrence [11,12]. Management of PTMC is
still a topic of hot debate due to varying natural history
of PTMC. The conservative “wait and watch” treatment
for PTMC has been advocated due to its benign clinical
course [13]. On the contrary, surgery has been recom-
mended as the treatment of choice for PTMC [14-16]. A
variety of clinical and pathological criteria are used to
determine the aggressive potential as well as risk of re-
currence in PTMC such as age, sex, focality, and lymph
node metastasis at diagnosis. However, PTMC is fre-
quently an incidental finding and the availability of these
clinicopathological criteria is circumspect at the time.
Haymart et. al observed that 78.5 percent of patients
had PTMC as an incidental finding on postsurgical pa-
thology report [17]. In addition, the use of ultrasono-
graphy to assess the above-mentioned criteria is restricted
by its own limitations of being operator dependent andnot accurate or sensitive enough; the sensitivity of ultra-
sonographic diagnosis for multifocality and lymph node
metastasis in the lateral compartment are 52.9% and
38.3%, respectively [18]. Thus, it is important to establish
a definite marker which would either complement the
existing criteria or act alone to differentiate aggressive
PTMC from non-aggressive cases and serve as an invalu-
able tool in clinical practice. Single-center retrospective
study of a cohort of 1669 patients with PTMC managed
from 1960 to 2007 proposed a scoring system to classify
recurrence risk [19]. The recurrence probability of pT3
PTMC appeared lower if radioiodine ablation was per-
formed, while in PTMCNx (lymph node status not known)
patients, multifocality was important in planning thera-
peutic strategies [19].
At present, there is a dearth of validated biomarkers
that have crossed the bridge from laboratory to clinic.
BRAF mutation has shown promising results in predict-
ing prognosis in conventional PTC, however its preva-
lence is distinctly lower (18%) in PTMC smaller than
5mm in diameter [20]. Cyclin D1 nuclear expression also
had inconclusive results [21,22]. S100A4 expression sig-
nificantly correlated with extra thyroidal extension and
multifocality in PTMC, but despite extensive studies,
this protein has not translated into a reliable biomarker
in the clinics [22]. Oligonucleotide array analysis
revealed that cell adhesion molecules were consistently
up-regulated in PTMC [23]. Further, another significant
finding was the absence of differences in the gene ex-
pression profiles of PTMC and PTC, hinting at the pos-
sibility that some PTMC might represent an early
detected stage of conventional PTC as opposed to being
a distinct entity [24]. This presents the plausibility that a
biomarker which has given reliable results in predicting
prognosis in PTC might be extrapolated for the same
use in PTMC.
Epithelial cell adhesion molecule (EpCAM) is a 40 kDa
transmembrane glycoprotein, comprised of an extracellu-
lar domain (EpEx), a single transmembrane domain and a
short 26 amino acid intracellular domain (Ep-ICD) [25].
Ep-ICD has been demonstrated to be frequently overex-
pressed in human malignancies by our group [26].
EpCAM plays a major role in a multitude of processes in-
cluding cell adhesion, proliferation, differentiation, cell
cycle regulation and is implicated in cancer signaling. Re-
cently, we reported nuclear and cytoplasmic accumulation
of Ep-ICD and loss of membranous EpEx to be a marker
for poor prognosis in thyroid cancer [27]. Taking all of the
above into consideration, we sought to explore the appli-
cation of EpCAM in answering the question of aggressive
potential in PTMC. The aim of this study was to discern
Ep-ICD and EpEx expression in metastatic and non-
metastatic PTMC. In addition, we defined a composite
representation of EpCAM staining, ESLI (Ep-ICD
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branous EpEx staining and nuclear and cytoplasmic Ep-
ICD accumulation. ESLI has recently been validated by us
in a cohort of 200 patients as a reliable tool for identifying
aggressive behavior in PTC [28]. In view of the above sta-
ted similar gene expressions of PTC and PTMC, we
sought to investigate the ability of this marker to better
answer the clinical question at hand.
Methods
Patients and materials
This study was approved by the Research Ethics Board
of Mount Sinai Hospital. The histopathology reports of
patients who underwent thyroid surgery at Mount Sinai
Hospital were reviewed. Only patients who had total
thyroidectomy as their primary mode of treatment were
selected in order to accurately assess the focality of
PTMC. Further inclusion criteria consisted of PTMC
size more than or equal to 5 mm which was based on li-
terature survey that demonstrated more aggressive be-
havior in PTMC of size ≥ 5 mm [22,29]. Cases with
thyroid surgery other than total thyroidectomy or tumor
size smaller than 5mm were excluded. Based on these
criteria, 36 PTMC patients were identified between 2006
and 2011. All thirty-six slides were reviewed by the path-
ologist (CM) to confirm the diagnosis of PTMC. IHC for
Ep-ICD and EpEx was performed in all these tissue sec-
tions as previously described by us [27]. During the
follow-up period, 2 of these patients had persistent di-
sease (no remission), 1 had recurrent disease (relapse
after remission) and the remaining 33 were disease free
during the defined time interval of 5 years.
Antibodies
Anti-human-EpCAM mouse monoclonal antibody MOC-
31 (AbD Serotec, Oxford, UK) recognizes an extracellular
component (EpEx) in the amino-terminal region of
EpCAM. α-Ep-ICD antibody 1144 [Epitomics Inc.
(Burlingame, CA)] recognizes the intracellular domain of
EpCAM, Ep-ICD.
Immunohistochemistry for EpEx and Ep-ICD expression in
PTMCs
Serial PTMC tissue sections (4 μm thickness) were depar-
affinized, hydrated in xylene and graded alcohol series.
Antigen retrieval was carried out using a microwave oven
in 0.01 M citrate buffer, pH 6.0; thereafter the slides were
treated with 0.3% H2O2 at room temperature for 30 mi-
nutes to block the endogenous peroxidase activity. After
blocking for non-specific binding with horse or goat
serum, the sections were incubated with anti-human anti-
bodies -EpEx mouse monoclonal antibody MOC-31 (dilu-
tion 1:200), or α- Ep-ICD rabbit monoclonal antibody
1144 (dilution 1:200) respectively and biotinylatedsecondary antibody (horse antimouse or goat anti-rabbit
respectively) for 30 minutes. The sections were subse-
quently incubated with VECTASTAIN Elite ABC Re-
agent (Vector laboratories, Burlington, Ontario, Canada)
and diaminobenzidine was used as the chromogen.
Hematoxylin was used as the counterstain for nuclei.
The primary antibody was replaced with isotype specific
IgG in PTMC used as the negative control. Colon cancer
tissue sections known to express Ep-ICD or EpEx were
used as positive controls in each batch of IHC analysis.
Evaluation of immunohistochemical staining
Sections were scored as positive if epithelial cells showed
immunopositivity in the plasma membrane, cytoplasm,
and/or nucleus when observed by two independent eva-
luators who were blinded to the clinical outcome. These
sections were scored as follows: 0, < 10% cells; 1, 10–30%
cells; 2, 31–50% cells; 3, 51–70% cells; and 4, > 70% cells
showed immunoreactivity. Sections were also scored
semi-quantitatively on the basis of intensity as follows: 0,
none; 1, mild; 2, moderate; and 3, intense. Finally, a total
score (ranging from 0 to 7) was obtained by adding the
scores of percentage positivity and intensity for the thyroid
cancer [26,27]. Loss of membranous EpEx was calculated as
the maximum total score of 7- score for membrane EpEx.
Ep-ICD subcellular Localization Index (ESLI)
ESLI was defined as sum of the IHC scores for accumu-
lation of nuclear and cytoplasmic Ep-ICD and loss of
membranous EpEx; ESLI = [Ep − ICDnuc + Ep − ICDcyt +
loss of membranous EpEx] [28].
Statistical analysis
Statistical analysis was performed with SPSS software
version 20.0. Categorical variables were presented by
number of cases and percentage. Fisher’s exact test was
used when comparing frequencies between groups. Con-
tinuous variables were presented by mean ± standard de-
viation (SD) or median with range. Independent T test
was used when comparing continuous variables between




Thirty-six patients met the inclusion and exclusion cri-
teria of the study. Eight patients were classified in the
metastatic group. All patients in the metastatic group
had lymph node metastasis at diagnosis. Two patients
had persistent disease and one patient had recurrence.
No patient had distant metastasis or death during the
follow up period. There were 28 patients in the non-
metastatic group.
Table 1 Patient characteristics distribution of the metastatic and non-metastatic PTMC
Patient characteristics Metastatic (n = 8) Non-metastatic (n = 28) P-value
Gender
Female 4 (50%) 23 (82.1%) 0.086
Male 4 (50%) 5 (17.9%)
Histological subtype
Classical 5 (62.5%) 11 (39.3%) 0.742
Follicular 3 (37.5%) 14 (50%)
Oncocytic 0 (0) 2 (7.1%)
Diffuse sclerosing 0 (0) 1 (3.6%)
Multifocal 6 (75%) 16 (57.1%) 0.441
Lymph node metastasis at diagnosis 8 (100%) 0 <0.001
Extrathyroidal extension 2 (25%) 3 (10.7%) 0.305
Angioinvasion 3 (37.5%) 2 (7.1%) 0.061
TNM stage
I&II 4 (50%) 26 (92.9%) 0.03
III&IV 4 (50%) 2 (7.1%)
I-131 No.
0 1 (12.5%) 24 (85.7%) <0.001
≥ 1 7 (87.5%) 4 (14.3%)
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non-metastatic PTMC
Clinicopathological features were compared between
metastatic and non-metastatic groups. Patients with me-
tastasis had advanced TNM stage compared to those with-
out (p = 0.03) and I-131 treatment was administered more
in the metastatic group (87.5% vs. 14.3%; p < 0.001)
(Table 1). Patients in the metastatic group were younger
in age (41.8 ± 12.5 vs. 55.8 ± 10.7 years; p = 0.003; Table 2).
No significant differences were found between the two
groups in terms of other clinicopathological variables,
including patients’ gender, tumor size, histological subtype,
multifocality, extrathyroidal extension and duration of fol-
low up (Table 1 and Table 2).
Immunohistochemical Ep-ICD and EpEx expression in
metastatic PTMC and non-metastatic PTMC
Patients with metastasis had reduced levels of membrane
EpEx than those without metastasis (4.64 ± 1.08 vs. 5.64 ±
1.51; p = 0.026) (Table 3 and Figure 1A and B). Patients
with metastatic PTMC had higher scores of Ep-ICD nu-
cleus and cytoplasm than the non-metastatic group (1.96 ±
0.86 vs. 1.22 ± 0.45; p = 0.007 and 5.37 ± 0.33 vs. 4.72 ±Table 2 Patient characteristics distribution (Mean ± SD) of the
Patient characteristics Metastatic (n = 8)
Age (year) 41.8 ± 12.5
Tumor size (cm) 0.86 ± 0.14
Duration of follow up (months) 31 ± 191.07; p = 0.016, respectively; Table 3 and Figure 1C and D).
PTMC with lymph node metastasis showed higher ESLI
scores as compared to the non-metastatic group (9.69 ±
2.01 vs. 7.30 ± 2.39 respectively; p = 0.008; Table 3).ESLI is a potential marker for aggressive PTMC
Box plot analysis revealed an increasing trend of Ep-ICD
cytoplasm, Ep-ICD nucleus, loss of membranous EpEx as
well as ESLI with lymph node metastasis (Figure 2A and
B) which adds credence to our hypothesis that aggressive
behavior in PTMC is characterized by loss of surface
EpCAM and accumulation of its intracellular domain Ep-
ICD. Dot plot analysis revealed similar trend of accumula-
tion of Ep-ICD in nucleus and cytoplasm in metastatic
PTMC (Figure 3A). Non-metastatic PTMC had strong
membrane EpEx staining which was reduced or lost with
more aggressive characteristics (Figure 3B). ROC curve
analysis showed area under the curve (AUC) for Ep-ICD
cytoplasm, Ep-ICD nucleus and loss of membranous EpEx
were 0.766 (p = 0.024), 0.783 (p = 0.016) and 0.757 (p =
0.029) respectively (Figure 4A, B and C respectively;
Table 3). ESLI, an index of aggressiveness, showed anmetastatic and non-metastatic group
Non-metastatic (n = 28) P-value
55.8 ± 10.7 0.003
0.76 ± 0.15 0.111
25 ± 19 0.238
Table 3 Subcellular localization of Ep-ICD and EpEx in metastatic and non-metastatic PTMC
Protein localization Metastatic (mean ± SD) Non-metastatic (mean ± SD) P-value AUC A.sig
EpEx cytoplasm 3.00 ± 1.67 1.91 ± 1.16 0.095 0.694 0.098
EpEx membrane 4.64 ± 1.08 5.64 ± 1.51 0.026 0.243 0.029
Loss of membranous EpEx 2.36 ± 1.08 1.36 ± 1.51 0.026 0.757 0.029
Ep-ICD nucleus 1.96 ± 0.86 1.22 ± 0.45 0.007 0.783 0.016
Ep-ICD cytoplasm 5.37 ± 0.33 4.72 ± 1.07 0.016 0.766 0.024
Ep-ICD membrane 1.30 ± 1.07 1.93 ± 1.61 0.348 0.391 0.351
ESLI (loss of membranous EpEx + Ep-ICDnuc + Ep-ICD cyto) 9.69 ± 2.01 7.30 ± 2.39 0.008 0.808 0.009
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tasis (p = 0.009) (Table 3 and Figure 4D).
Discussion
PTMC patients have excellent survival statistics and a very
low mortality rate of 0.34%, therefore, the current thera-
peutic strategies are mainly focused on reducing morbidity
such as tumor recurrence or metastasis. PTMC patients
with cervical lymph node metastasis at diagnosis had more
events of recurrence than PTMC patients without nodal
metastasis [10,14]. Moreover, the presence of lymph
node metastasis at diagnosis increased the relative risk of
distant metastasis 11.2 fold [10]. Thus, nodal metastasis at






Figure 1 Immunohistochemical analysis of EpEx and Ep-ICD expressio
photomicrographs show immunostaining of EpEx and Ep-ICD in PTMC. Stro
metastatic group (A), whereas decreased staining of membranous EpEx wa
show predominant cytoplasmic localization of Ep-ICD and no detectable n
strong cytoplasmic Ep-ICD accumulation (D). (E) depicts the negative contrand distant metastasis in PTMC. However, lymph node
sampling is not routinely performed in all thyroid surge-
ries, especially in cases where thyroid cancer is not sus-
pected prior to surgery, which compounds the issue in the
finding of incidental PTMC.
Current American Joint Committee on Cancer (AJCC)
TNM staging recommends using a select few clinicopatho-
logical variables to determine prognosis in thyroid cancer
patients [30]. Age of the patient is a well-known prognostic
factor in differentiated thyroid cancer with age more than
or equal to 45 years having a worse outcome [30]. Notably,
PTMC patients with lymph node metastasis were younger
than PTMC patients without lymph node metastasis in this
study. This finding has also been confirmed in a recentB
Metastatic PTMC
D
n in papillary thyroid microcarcinoma. The representative
ng membranous EpEx immunostaining was observed in the non-
s observed in aggressive PTMC cases (B). The non-metastatic PTMC
uclear Ep-ICD staining (C), while the aggressive cases show nuclear and
ol. Original magnification x 400.
Figure 2 Box plot analysis of Ep-ICD and EpEx staining in PTMC. Comparison of Ep-ICD and EpEx immunostaining in metastatic and non-
metastatic PTMCs shows increase in nuclear and cytoplasmic Ep-ICD and loss of membranous EpEx in the metastatic PTMC. EpEx membrane is
correspondingly reduced in the metastatic PTMC group (A). ESLI showed significant correlation with lymph node metastasis (B). Abbreviations in
the figure: LN+, lymph node metastasis; LN-, no lymph node metastasis; nuc, nucleus; cyto, cytoplasm; memb, membrane.
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suggesting younger patients may have more aggressive dis-
ease, especially in case of occult PTMC. These challenges
along with presence of divisive data on the prognosis of
PTMC urge accurate categorization of the aggressive subset
of this malignancy. Hence, there is an urgent unmet need
to identify a universal undisputed biomarker that, inde-
pendently or in conjunction with known criteria, serves to
stratify PTMCs according to their metastatic potential.
It is imperative to understand the mechanism of
EpCAM activation and the relationship between altera-
tions in the levels of its intra- and extra- cellular
domains. The shedding of extracellular EpEx triggers
intramembranous cleavage of the remaining EpCAMFigure 3 Dot plot analysis of Ep-ICD and membranous EpEx expressio
the distribution of total IHC scores for Ep-ICD (A); EpEx and ESLI (B). The ve
Increased nuclear expression of Ep-ICD was more frequently observed in th
(A). High membrane EpEx expression was observed in non-metastatic PTM
in most of the aggressive PTMC cases analyzed (B). An increase in ESLI was
metastatic PTMCs (B). Abbreviations: NM, non-metastatic; M, metastatic.molecule by tumor necrosis factor-alpha convertase
(TACE) and γ-secretase complex (containing presenilin2
as a catalytic subunit). This is turn activates the release
of the intracellular domain Ep-ICD which binds to β-
catenin and FHL2 to translocate into the nucleus. The
ensuing complex initiates a cascade of events leading up
to and participating in increased gene transcription and
cell proliferation [32].
In this study, metastatic PTMCs showed higher ex-
pression of nuclear Ep-ICD compared to the non-
metastatic PTMCs. Moreover, membranous EpEx was
reduced in the PTMC group with lymph node metasta-
sis. Notably, in support of our findings, loss of mem-
branous EpCAM has been significantly associated withn in papillary thyroid microcarcinoma patients. Dot plot shows
rtical axis gives the IHC score as described in the Methods section.
e metastatic PTMC group as compared to the non-metastatic PTMCs
Cs, whereas decreased membranous expression of EpEx was observed
observed in the metastatic PTMC group as compared to the non-
B.   Ep-ICD nucleusA.   Ep-ICD Cytoplasm
C. Loss of membranous EpEx
AUC=0.766 AUC=0.783
AUC=0.757 AUC=0.808
D.                ESLI
Figure 4 ROC curve analysis of cytoplasmic and nuclear Ep-ICD, loss of membranous EpEx and ESLI in PTMC. The vertical axis represents
sensitivity and the horizontal axis represents 1-specificity in ROC curves of cytoplasmic (A) and nuclear Ep-ICD (B), loss of membranous EpEx (C)
and ESLI (D). The area under the curve (AUC) values and significance values for the two groups are summarized in Table 3.
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cer as well [33]. Furthermore, we introduced a new
index of aggressiveness, ESLI, in PTMC that demon-
strated effectiveness of the combination of subcellular
(cytoplasmic and nuclear) localized staining in distin-
guishing the metastatic PTMC from non-metastatic, as
compared to Ep-ICD and EpEx alone. The findings of
our study need to be validated in a larger cohort to be
applicable in clinical practice. A larger number of cases
could also help correlating Ep-ICD expression with sur-
vival in PTMC patients, which was a limitation of this
study. The risk of lymph node recurrence increased
when multifocality was present [10], which could not be
established in this study due to limited sample size.
A randomized control trial would be the best way to
evaluate the relevance of this marker in the clinics. The
novelty of our study lies in the fact that it is the first to ex-
plore the expression of Ep-ICD, EpEx and ESLI in PTMC.
In addition, we bring a composite marker in the form of
ESLI which has proven more valuable than Ep-ICD or
EpEx alone, in answering the pertinent question ofaggressive potential of PTMC. The use of ESLI for predict-
ing lymph node metastasis in PTMC could prevent future
recurrences or distant metastasis by allowing for more ag-
gressive treatment. The ability to differentiate indolent
PTMC from metastatic would help conserve vital time
and resources by effectively directing aggressive manage-
ment to the patients who require it while at the same time,
saving patients with essentially benign disease from un-
necessary treatment. Thus, Ep-ICD, EpEx and ESLI are
plausible candidate markers to elucidate the myriad unre-
quited queries that surround the PTMC enigma.
Conclusion
This study provides new evidence in support of the po-
tential of Ep-ICD and EpEx when incorporated with
ESLI to serve as markers for identification of aggressive
PTMC from non-aggressive PTMC.
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